Meloxicam Tablet
Product Images NDC 11788-046

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Meloxicam (NDC 11788-046). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aiping Pharmaceutical, Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Container-label-15mg (Container 15mg 1000s)

Meloxicam Tablets, USP 15 mg oral tablets in a 1000 count container label. The label displays the NDC 11788-047-10 and identifies AiPing Pharmaceutical, Inc as the labeler. The packaging is marked for prescription use only and specifies storage instructions and manufacturer details for A&Z Pharmaceutical, Inc.*

FDA Label Image

Container-label-7.5mg (Container 7.5mg 1000s)

Meloxicam Tablets USP 7.5 mg oral tablets in a 1000-count container label. The label shows the NDC 11788-046-10 and directions to store at 20°C to 25°C. It is manufactured for AiPing Pharmaceutical, Inc. with A&Z Pharmaceutical, Inc. as the manufacturer. The label includes a barcode and the AiPing logo.*

FDA Label Image

Mg1 (Mg1)

This text panel contains warnings related to NSAIDs usage, cautioning against taking NSAIDs immediately before or after coronary artery bypass graft surgery and advising consultation with healthcare providers following a recent heart attack due to increased risk of another heart attack.*

FDA Label Image

Mg2 (Mg2)

A text panel providing information on risk factors for developing ulcers or bleeding with NSAID use, including history of stomach ulcers, use of corticosteroids or anticoagulants, higher NSAID doses, older age, poor health, smoking, alcohol consumption, advanced liver disease, and bleeding problems.*

FDA Label Image

Mg3 (Mg3)

Drug Facts text panel for Meloxicam tablets, describing dosage warnings including liver or kidney problems, allergies, and use during pregnancy or breastfeeding. It advises consulting healthcare professionals and lists additional precautions and directions related to alcohol use and other health conditions.*

FDA Label Image

Mg4 (Mg4)

The image shows a Drug Facts text panel providing warnings and symptoms to watch for, such as shortness of breath, chest pain, slurred speech, and swelling of the face or throat. It is related to the medication Meloxicam, highlighting potential serious side effects.*

FDA Label Image

Mg5 (Mg5)

A partial text panel listing side effects associated with a medication, including symptoms such as nausea, diarrhea, skin rash, vomiting blood, and unusual weight gain. The text is in bullet point format and appears to be part of patient safety or warning information for the drug Meloxicam tablets.*

FDA Label Image

Structural (Structural Formula)

Chemical structure diagram of meloxicam, showing its molecular arrangement with labeled sulfonamide and thiazole groups, consistent with its chemical composition as the active ingredient in MELOXICAM tablets.*

FDA Label Image

Table 1a (Table 1a)

A data table presenting adverse event percentages occurring in 2% or more of Meloxicam patients during a 12-week osteoarthritis placebo- and active-controlled trial. It compares placebo, Meloxicam 7.5 mg daily, Meloxicam 15 mg daily, and Diclofenac 100 mg daily groups across categories like gastrointestinal, body as a whole, central and peripheral nervous system, respiratory, and skin events.*

FDA Label Image

Table 1b (Table 1b)

Adverse events table showing percentages of side effects occurring in 2% or more of patients treated with Meloxicam 7.5 mg or 15 mg daily versus placebo during two 12-week rheumatoid arthritis placebo-controlled trials. Categories include gastrointestinal disorders, general disorders, infections, musculoskeletal disorders, nervous system, and skin disorders with corresponding event rates for each treatment group.*

FDA Label Image

Table 2.1 (Table 2.1)

A data table listing various adverse reactions categorized by body system. It includes effects on the body as a whole, cardiovascular, central and peripheral nervous system, gastrointestinal, heart rate and rhythm, hematologic, liver and biliary system, metabolic and nutritional, psychiatric, respiratory, skin and appendages, special senses, and urinary system.*

FDA Label Image

Table 2 (Table 2)

A data table presenting adverse event percentages occurring in 2% or more of Meloxicam patients during 4 to 6 week and 6 month active-controlled osteoarthritis trials. It compares occurrences between Meloxicam 7.5 mg and 15 mg daily dosages across various body systems including gastrointestinal, nervous, hematologic, musculoskeletal, psychiatric, respiratory, skin, and urinary categories.*

FDA Label Image

Table 3.1 (Table 3.1)

A drug interaction and clinical impact table listing lithium, methotrexate, cyclosporine, NSAIDs and salicylates, and pemetrexed in relation to meloxicam use. Each section details potential clinical impacts and recommended interventions during concomitant use with meloxicam, including monitoring and dosing guidance.*

FDA Label Image

Table 3 (Table 3)

A data table titled 'Clinically Significant Drug Interactions with Meloxicam' listing drugs that interfere with hemostasis, including anticoagulants, aspirin, ACE inhibitors, angiotensin receptor blockers, beta-blockers, and diuretics. For each drug group, it describes the clinical impact and recommended interventions when used concomitantly with meloxicam.*

FDA Label Image

Image Description (Table 4)

A pharmacokinetic data table presenting single dose and steady-state parameters for oral 7.5 mg and 15 mg Meloxicam in various populations, including healthy male adults, elderly males and females, and patients with renal failure and hepatic insufficiency. Parameters listed include Cmax, tmax, t1/2, CL/f, and Vz/f with corresponding mean values and coefficient of variation percentages.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.